{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:49:03Z","timestamp":1763768943438,"version":"3.45.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:00:00Z","timestamp":1795046400000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cpet.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:08:54Z","timestamp":1761235734000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Kimberly","family":"Luddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Gravon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Robertson-Tessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gatenby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cpet.2025.08.006_bib1","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot Study","volume":"27","author":"Prive","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2025.08.006_bib3","unstructured":"RA., G., The approaching Darwinian era in oncology. Cancer Research, 2025. In press."},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000148914","article-title":"Dose-dense chemotherapy: principles, clinical results and future perspectives","volume":"3","author":"Citron","year":"2008","journal-title":"Breast Care"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.006_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/0284186X.2017.1329593","article-title":"Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts","volume":"56","author":"Matikas","year":"2017","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","article-title":"A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrc.2016.28","article-title":"Chemotherapy: preventing competitive release","volume":"16","author":"Seton-Rogers","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpet.2025.08.006_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2307\/1933500","article-title":"The influence of interspecific competition and other factors on the distribution of the barnacle Chthamalus stellatus","volume":"42","author":"Connell","year":"1961","journal-title":"Ecology"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib9","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.cpet.2025.08.006_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215225","article-title":"A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2025.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76284","article-title":"Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes","volume":"11","author":"Zhang","year":"2022","journal-title":"eLife"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.006_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.neo.2021.06.013","article-title":"Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics","volume":"23","author":"Brady-Nicholls","year":"2021","journal-title":"Neoplasia"},{"issue":"7425","key":"10.1016\/j.cpet.2025.08.006_bib13","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/491S55a","article-title":"Perspective: finding cancer's first principles","volume":"491","author":"Gatenby","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.006_bib14","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/ije\/dyl185","article-title":"The population dynamics of cancer: a Darwinian perspective","volume":"35","author":"Vineis","year":"2006","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib15","first-page":"729","article-title":"An evolutionary model for initiation, promotion, and progression in carcinogenesis","volume":"32","author":"Vincent","year":"2008","journal-title":"Int J Oncol"},{"issue":"15","key":"10.1016\/j.cpet.2025.08.006_bib16","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.133.151001","article-title":"Inflationary butterfly effect: nonperturbative dynamics from small-scale features","volume":"133","author":"Caravano","year":"2024","journal-title":"Phys Rev Lett"},{"issue":"7246","key":"10.1016\/j.cpet.2025.08.006_bib17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.006_bib18","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpet.2025.08.006_bib19","doi-asserted-by":"crossref","unstructured":"Zhang J, C., J, Brown J, Gatenby R, Evolution-based mathematical models significantly prolong response to Abiraterone in metastatic castrate resistant prostate cancer and identify strategies to further improve outcomes Elife, 2022.","DOI":"10.7554\/eLife.76284.sa2"},{"key":"10.1016\/j.cpet.2025.08.006_bib20","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1038\/ncomms6499","article-title":"Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations","volume":"5","author":"Gatenby","year":"2014","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.cpet.2025.08.006_bib21","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/0008-5472.CAN-22-2558","article-title":"Intermetastatic and intrametastatic heterogeneity shapes adaptive therapy cycling dynamics","volume":"83","author":"Gallaher","year":"2023","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.006_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","article-title":"Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies","volume":"78","author":"Gallaher","year":"2018","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.cpet.2025.08.006_bib23","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1158\/0008-5472.CAN-19-3981","article-title":"Searching for goldilocks: how evolution and ecology can help uncover more effective patient-specific chemotherapies","volume":"80","author":"Park","year":"2020","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.006_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","article-title":"Integrating evolutionary dynamics into cancer therapy","volume":"17","author":"Gatenby","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.cpet.2025.08.006_bib25","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-25-0351","article-title":"Adaptive therapy exploits fitness deficits in chemotherapy-resistant ovarian cancer to achieve long-term tumor control","volume":"85","author":"Hockings","year":"2025","journal-title":"Cancer Res"},{"issue":"327","key":"10.1016\/j.cpet.2025.08.006_bib27","doi-asserted-by":"crossref","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"Enriquez-Navas","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4_suppl","key":"10.1016\/j.cpet.2025.08.006_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS245","article-title":"A phase IIa study of sequential (\u201cfirst strike, second strike\u201d) therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib29","first-page":"15","article-title":"Budget impact of adaptive abiraterone therapy for castration-resistant prostate cancer","volume":"14","author":"Mason","year":"2021","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.cpet.2025.08.006_bib30","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1158\/0008-5472.CAN-09-1354","article-title":"Lessons from applied ecology: cancer control using an evolutionary double bind","volume":"69","author":"gatenby","year":"2009","journal-title":"Cancer Res"},{"issue":"3 Pt 1","key":"10.1016\/j.cpet.2025.08.006_bib31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.006_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00259-016-3548-5","article-title":"Radioiodine - the success story of nuclear medicine : 75th anniversary of the first use of Iodine-131 in humans","volume":"44","author":"McCready","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2025.08.006_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in radioligand theranostics in oncology","volume":"28","author":"Lawal","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41420-023-01778-3","article-title":"Carrier systems of radiopharmaceuticals and the application in cancer therapy","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.cpet.2025.08.006_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2023.100477","article-title":"Current and upcoming radionuclide therapies in the direction of precision oncology: a narrative review","volume":"10","author":"Shah","year":"2023","journal-title":"Eur J Radiol Open"},{"issue":"6","key":"10.1016\/j.cpet.2025.08.006_bib36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2967\/jnumed.121.262017","article-title":"Effects of (225)Ac-Labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis","volume":"63","author":"Lee","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.08.006_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/1536012118776068","article-title":"PSMA theranostics: current status and future directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol Imaging"},{"issue":"23","key":"10.1016\/j.cpet.2025.08.006_bib38","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.006_bib39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.006_bib41","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-Specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2025.08.006_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2967\/jnumed.120.256263","article-title":"Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer","volume":"62","author":"Stuparu","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00259-023-06388-w","article-title":"A look into the future: the role of PSMA beyond prostate cancer","volume":"51","author":"Pellegrino","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.006_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","article-title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","volume":"21","author":"Eapen","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/diagnostics3040344","article-title":"Induction of anti-tumor immune responses by peptide receptor radionuclide therapy with (177)Lu-DOTATATE in a murine model of a human neuroendocrine tumor","volume":"3","author":"Wu","year":"2013","journal-title":"Diagnostics"},{"issue":"7381","key":"10.1016\/j.cpet.2025.08.006_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.cpet.2025.08.006_bib47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.006_bib48","article-title":"A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging Theranostic agents in prostate cancer","volume":"14","author":"Alam","year":"2022","journal-title":"Cureus"},{"issue":"18","key":"10.1016\/j.cpet.2025.08.006_bib49","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1158\/0008-5472.CAN-17-0164","article-title":"Androgen receptor variants mediate DNA repair after prostate cancer irradiation","volume":"77","author":"Yin","year":"2017","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.cpet.2025.08.006_bib50","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/onc.2014.238","article-title":"DNA damage response and prostate cancer: defects, regulation and therapeutic implications","volume":"34","author":"Karanika","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.cpet.2025.08.006_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/214074","article-title":"Cellular stress responses: cell survival and cell death","volume":"2010","author":"Fulda","year":"2010","journal-title":"Int J Cell Biol"},{"issue":"6","key":"10.1016\/j.cpet.2025.08.006_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1189\/jlb.0313153","article-title":"Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation","volume":"94","author":"Muralidharan","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"1194","key":"10.1016\/j.cpet.2025.08.006_bib53","article-title":"Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance","volume":"8","author":"Zingoni","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpet.2025.08.006_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/bs.ircmb.2023.02.003","article-title":"Combining radiotherapy and NK cell-based therapies: the time has come","volume":"378","author":"Baude","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.cpet.2025.08.006_bib55","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -Extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cpet.2025.08.006_bib56","article-title":"Combined use of NK cells and radiotherapy in the treatment of solid tumors","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.006_bib57","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/0008-5472.CAN-13-1703","article-title":"RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma","volume":"74","author":"Lam","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpet.2025.08.006_bib58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fimmu.2013.00508","article-title":"The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells","volume":"4","author":"Cerboni","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpet.2025.08.006_bib59","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29259","article-title":"STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression","volume":"3","author":"Le Bert","year":"2014","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib2","article-title":"Extending the functional lifespan of natural killer (NK) cells: towards durable cytotoxicity in NK-cell based immunotherapy","volume":"4","author":"Luddy","year":"2025","journal-title":"BMJ Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.006_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.cpet.2025.08.006_bib61","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/ajt.13565","article-title":"Natural killer cells and liver transplantation: orchestrators of rejection or tolerance?","volume":"16","author":"Harmon","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cpet.2025.08.006_bib62","article-title":"Natural killer cell infiltration in prostate cancers predict improved patient outcomes","author":"Zorko","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.006_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111702","article-title":"NK cells can preferentially target prostate cancer stem-like cells via the TRAIL\/DR5 signaling pathway","volume":"11","author":"Seki","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.006_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119521","article-title":"NK cells in cancer: mechanisms of dysfunction and therapeutic potential","volume":"24","author":"Portale","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.cpet.2025.08.006_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.006_bib66","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.006_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cpet.2025.08.006_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.006_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CJI.0000000000000250","article-title":"Natural killer cell homing and persistence in the bone marrow after adoptive immunotherapy correlates with better leukemia control","volume":"42","author":"Grzywacz","year":"2019","journal-title":"J Immunother"},{"issue":"7","key":"10.1016\/j.cpet.2025.08.006_bib70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/eji.201747378","article-title":"The bone marrow is patrolled by NK cells that are primed and expand in response to systemic viral activation","volume":"48","author":"Milo","year":"2018","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.006_bib71","first-page":"210","article-title":"Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"10.1016\/j.cpet.2025.08.006_bib72","article-title":"Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cpet.2025.08.006_bib73","doi-asserted-by":"crossref","first-page":"S1333","DOI":"10.21037\/tcr.2016.12.27","article-title":"Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity","author":"Madan","year":"2016","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.006_bib74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cpet.2025.08.006_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251347857","article-title":"Immunotherapy in metastatic prostate cancer","volume":"17","author":"Dwyer","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"26","key":"10.1016\/j.cpet.2025.08.006_bib76","first-page":"2495","article-title":"Lutetium-177-PSMA-617 for prostate cancer. Reply","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.006_bib77","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2967\/jnumed.124.268857","article-title":"MHC-I-driven antitumor immunity counterbalances low absorbed doses of radiopharmaceutical therapy","volume":"66","author":"Constanzo","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.08.006_bib78","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fnume.2024.1331364","article-title":"Immunological effects of radiopharmaceutical therapy","volume":"4","author":"Shea","year":"2024","journal-title":"Frontiers in Nuclear Medicine"},{"issue":"13","key":"10.1016\/j.cpet.2025.08.006_bib79","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.7150\/thno.54881","article-title":"Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy","volume":"11","author":"Jagodinsky","year":"2021","journal-title":"Theranostics"},{"issue":"602","key":"10.1016\/j.cpet.2025.08.006_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.006_bib81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:44:29Z","timestamp":1763768669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859825000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1556859825000860"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.08.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}